Literature DB >> 3293664

Degradation of thymopentin by human lymphocytes: evidence for aminopeptidase activity.

A A Amoscato1, A Balasubramaniam, J W Alexander, G F Babcock.   

Abstract

Thymopentin (Arg-Lys-Asp-Val-Tyr) was shown to be degraded in vitro by human lymphocytes into two main fragments; the tetrapeptide Lys-Asp-Val-Tyr and the tripeptide Asp-Val-Tyr. Degradation products were identified by HPLC and amino-acid analysis. Analysis of the time-course of degradation revealed a 'stepwise' degradative event beginning at the N-terminal. The degradation of thymopentin after the first 10 min, as well as the formation of the tetrapeptide (5-30 min) were essentially curvilinear. Degradation of the tripeptide, was linear. Upon screening a panel of compounds that inhibit enzymatic activity, bestatin, amastatin and 1,10-phenanthroline were shown to be the most effective. Bestatin and amastatin caused an 85-90% inhibition of thymopentin degrading activity with IC50 values of 7.1 x 10(-6) M and 4.5 x 10(-9) M, respectively. 1,10-Phenanthroline completely inhibited the degradative process with an IC50 of 2 x 10(-4) M. When the tetrapeptide Lys-Asp-Val-Tyr was used as the starting substrate, similar IC50 values were seen for amastatin, bestatin and 1,10-phenanthroline. The importance of divalent metal ions in the degradative event was demonstrated not only by the effect of 1,10-phenanthroline, but also by the ability of Zn2+ and Co2+ to reverse the inhibition of 1,10-phenanthroline (at its IC50) to activities near control values (no inhibitor). These data strongly suggest that an aminopeptidase(s) is responsible for the degradative activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293664     DOI: 10.1016/0167-4838(88)90190-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  The aminopeptidase activity in the human T-cell lymphoma line (Jurkat) is not at the cell surface and is not aminopeptidase N (CD-13).

Authors:  H Murray; A J Turner; A J Kenny
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

2.  Implantable sandwich PHBHHx film for burst-free controlled delivery of thymopentin peptide.

Authors:  Ke Peng; Chengyu Wu; Guoxu Wei; Jinghui Jiang; Zhirong Zhang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2018-04-07       Impact factor: 11.413

3.  Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers.

Authors:  Jing Wang; Wan-Liang Lu; Gong-Wen Liang; Ke-Chun Wu; Chun-Guang Zhang; Xuan Zhang; Jian-Cheng Wang; Hua Zhang; Xue-Qing Wang; Qiang Zhang
Journal:  Peptides       Date:  2005-10-19       Impact factor: 3.750

4.  Development of a Highly Efficient Hybrid Peptide That Increases Immunomodulatory Activity Via the TLR4-Mediated Nuclear Factor-κB Signaling Pathway.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Matthew Koci; Dayong Si; Baseer Ahmad; Junhao Cheng; Junyong Wang
Journal:  Int J Mol Sci       Date:  2019-12-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.